ADAPTherapeutics offers advanced, end-to-end discovery services designed to support biotechnology, pharmaceutical, and academic partners in the development of innovative therapies for degenerative and age-related diseases. Built on a proprietary transcriptomics-driven platform, our services integrate phenotype-based screening with advanced transcriptomic analysis and computational approaches to identify and prioritize compounds capable of modulating pathological gene expression programs. We support projects from early target and mechanism exploration through hit identification, validation, and preclinical readiness, delivering high-quality data, actionable insights, and flexible collaboration models. Our service approach is tailored, science-driven, and partnership-oriented, enabling efficient decision-making, reduced development risk, and accelerated translation from complex biology to therapeutic opportunity.